Scientists said the results were 'off the charts' following ... lorlatinib to provide a new standard first-line treatment for patients with ALK-positive lung cancer. Debra Montague, chair or ...

Scientists have hailed the drug, called lorlatinib, for its “off the charts” results after ... “Research like this is vital to find new ways to treat lung cancer and help more people survive ...

Samantha Murrell shares her journey with stage 4 NSCLC, a form of lung cancer. From her diagnosis to finding strength in treatment and support, she offers hopeful advice to others. New findings ...